Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Annals of Hematology|April 22, 1999
Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosineU Jehn, R Bartl, H Dietzfelbinger, et al.Investigational New Drugs|January 1, 1996
Clinical phase I and pharmacokinetic trial of the new titanium complex budotitaneT Schilling, K B Keppler, M E Heim, et al.Medizinische Klinik|June 10, 1977
[Clinical observations to characterize splenomegalic immunocytomas (author's transl)]H Theml, A Burger, E Keiditsch, et al.Cancer|June 5, 1999
Extramedullary plasmacytoma: tumor occurrence and therapeutic conceptsC Alexiou, R J Kau, H Dietzfelbinger, et al.Human Pathology|July 22, 1998
Molecular evidence of bone marrow involvement in advanced case ot Tgammadelta lymphoma with secondary myelofibrosisG Weirich, M Sandherr, C Fellbaum, et al.Investigational New Drugs|May 1, 1993
Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD)S Danhauser-Riedl, E Hausmann, H D Schick, et al.Age and Ageing|November 1, 1994
A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic strokeR Dumas, F Woitinas, M Kutnowski, et al.Blood|February 25, 1999
Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemiaM Hallek, I Langenmayer, C Nerl, et al.British Journal of Haematology|August 1, 1996
Interferon-alpha 2b (IFN alpha) for early-phase chronic lymphocytic leukaemia with high risk for disease progression: results of a randomized multicentre studyI Langenmayer, C Nerl, W Knauf, et al.Deutsche Medizinische Wochenschrift (1946)|November 24, 2006
[Treatment of chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists]W Abenhardt, D Bosse, L Böning, et al.Pageof 3